AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$ACOG

Opaleye Management Inc. purchased $271K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 31,763 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.53 ($8.47–$8.57, $0.27M total) across 2 trades over 2026-09-24 to 2026-09-25.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Sep 28, 2026, 11:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Neutral
medium confidence
Mentioned
$ACOG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The disclosed purchase adds modest buying pressure but is unlikely to affect broader market sentiment.

02

Market read

Primary disclosure of a small insider buy; limited trading relevance.

03

What to watch

Alpha Cognition's recent price volatility and upcoming product milestones may be more material drivers.

Relevance 5/10Novelty 4/10Timing: post-market filing today

Background

SEC Form 4 filing reports insider transactions; Opaleye Management is a 10% owner of Alpha Cognition.

Company-level read

Ticker impact

$ACOGNeutralMedium confidence
Context

Form 4 disclosed Opaleye Management bought 31,763 shares of Alpha Cognition at $8.53 avg, increasing its stake to over 3.2M shares.

Expected impact

likely limited upward pressure as market digests insider buying.

Evidence & confidence

The transaction amount (~$270K) is modest; while insider buying is positive, it is unlikely to move the stock significantly.

Market effects

Sector

Minimal impact on AI/tech sector; insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio adjustment rather than a strong endorsement.

Key entities

  • Insider
    Opaleye Management Inc.

    10% owner of Alpha Cognition, reported purchase of 31,763 shares.

  • Company
    Alpha Cognition Inc.

    AI-focused firm whose stock saw a small insider purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min